49 results on '"Delgado‐Sanz, Concepción"'
Search Results
2. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain : nationwide seroepidemiological study
- Author
-
ENE-COVID Study Group, Pastor-Barriuso, Roberto, Pérez-Gómez, Beatriz, Hernán, Miguel A, Pérez-Olmeda, Mayte, Yotti, Raquel, Oteo-Iglesias, Jesús, Sanmartín, Jose L, León-Gómez, Inmaculada, Fernández-García, Aurora, Fernández-Navarro, Pablo, Cruz, Israel, Martín, Mariano, Delgado-Sanz, Concepción, de Larrea, Nerea Fernández, Paniagua, Jose León, Muñoz-Montalvo, Juan F, Blanco, Faustino, Larrauri, Amparo, and Pollán, Marina
- Published
- 2020
3. Data Management in EpiGraph COVID-19 Epidemic Simulator
- Author
-
Guzmán-Merino, Miguel, primary, Durán, Christian, additional, Marinescu, Maria-Cristina, additional, Delgado-Sanz, Concepción, additional, Gomez-Barroso, Diana, additional, Carretero, Jesus, additional, and Singh, David E., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Estimación de la incidencia real de la COVID-19 en España
- Author
-
Cublier Martínez, Aymar, primary, Gómez-Barroso, Diana, additional, Delgado-Sanz, Concepción, additional, Monge, Susana, additional, Cascajo, Alberto, additional, Marinescu, María Cristina, additional, Larrauri, Amparo, additional, Carretero, Jesús, additional, and E. Singh, David, additional
- Published
- 2024
- Full Text
- View/download PDF
5. Monitorización de COVID-19 grave en España: comparación de tres sistemas en las temporadas 2021/22 y 2022/23
- Author
-
Lozano-Álvarez, Marcos, primary, Delgado-Sanz, Concepción, additional, Mazagatos-Ateca, Clara, additional, Galindo-Carretero, Silvia, additional, Pérez-Gimeno, Gloria, additional, Rojas-Benedicto, Ayelén, additional, Fontán-Vela, Mario, additional, Larrauri-Cámara, Amparo, additional, and Monge-Corella, Susana, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Impact of Influenza Vaccination on the Burden of Severe Influenza in the Elderly: Spain, 2017–2020
- Author
-
Mazagatos, Clara, primary, Delgado-Sanz, Concepción, additional, Milagro, Ana, additional, Liébana-Rodríguez, María, additional, and Larrauri, Amparo, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Estimación de la incidencia real de la COVID-19 en España Real COVID-19 incidence rate estimate in Spain.
- Author
-
Martínez, Aymar Cublier, Gómez-Barroso, Diana, Delgado-Sanz, Concepción, Monge, Susana, Cascajo, Alberto, Marinescu, María Cristina, Larrauri, Amparo, Carretero, Jesús, and Singh, David E.
- Subjects
WORLD Wide Web ,MEDICAL information storage & retrieval systems ,TIME series analysis ,DESCRIPTIVE statistics ,COMMUNICATION ,ELECTRONIC health records ,COVID-19 ,DISEASE incidence ,ACCESS to information - Abstract
Copyright of Revista Espanola de Comunicacion en Salud is the property of Asociacion Espanola de Comunicacion Sanitaria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
8. Corrigendum: Simulation of COVID-19 propagation scenarios in the Madrid metropolitan area
- Author
-
Singh, David E., primary, Marinescu, Maria-Cristina, additional, Guzmán-Merino, Miguel, additional, Durán, Christian, additional, Delgado-Sanz, Concepción, additional, Gomez-Barroso, Diana, additional, and Carretero, Jesus, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
- Author
-
Adlhoch, Cornelia, primary, Delgado-Sanz, Concepción, additional, Carnahan, AnnaSara, additional, Larrauri, Amparo, additional, Popovici, Odette, additional, Bossuyt, Nathalie, additional, Thomas, Isabelle, additional, Kynčl, Jan, additional, Slezak, Pavel, additional, Brytting, Mia, additional, Guiomar, Raquel, additional, Redlberger-Fritz, Monika, additional, Maistre Melillo, Jackie, additional, Melillo, Tanya, additional, van Gageldonk-Lafeber, Arianne B., additional, Marbus, Sierk D., additional, O’Donnell, Joan, additional, Domegan, Lisa, additional, Gomes Dias, Joana, additional, and Olsen, Sonja J., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Influenza hospitalisations in Spain between the last influenza and COVID-19 pandemic (2009–2019)
- Author
-
Canelas-Fernández, Javier, primary, Mazagatos, Clara, additional, Delgado-Sanz, Concepción, additional, and Larrauri, Amparo, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Exceso de mortalidad relacionado con la gripe en España en el invierno de 2012
- Author
-
León-Gómez, Inmaculada, Delgado-Sanz, Concepción, Jiménez-Jorge, Silvia, Flores, Víctor, Simón, Fernando, Gómez-Barroso, Diana, Larrauri, Amparo, and de Mateo Ontañón, Salvador
- Published
- 2015
- Full Text
- View/download PDF
12. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020
- Author
-
Adlhoch, Cornelia, Delgado-Sanz, Concepción, Carnahan, AnnaSara, Larrauri, Amparo, Popovici, Odette, Bossuyt, Nathalie, Thomas, Isabelle, Kynčl, Jan, Slezak, Pavel, Brytting, Mia, Guiomar, Raquel, Redlberger-Fritz, Monika, Maistre Melillo, Jackie, Melillo, Tanya, van Gageldonk-Lafeber, Arianne B, Marbus, Sierk D, O'Donnell, Joan, Domegan, Lisa, Gomes Dias, Joana, and Olsen, Sonja J
- Subjects
fatal outcome ,antiviral treatment ,surveillance ,risk factors ,epidemiology ,clinic ,hospital ,EU ,Influenza ,influenza virus - Published
- 2023
13. COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test negative design study based on SARI sentinel surveillance in Spain
- Author
-
Ateca, Clara Mazagatos, primary, Delgado-Sanz, Concepción, additional, Monge, Susana, additional, Pozo, Francisco, additional, Oliva, Jesús, additional, Sandonis, Virginia, additional, Gandarillas, Ana, additional, Quiñones-Rubio, Carmen, additional, Ruiz-Sopeña, Cristina, additional, Gallardo-García, Virtudes, additional, Basile, Luca, additional, Barranco-Boada, María Isabel, additional, Hidalgo-Pardo, Olga, additional, Vazquez-Cancela, Olalla, additional, García-Vázquez, Miriam, additional, Fernández-Sierra, Amelia, additional, Milagro-Beamonte, Ana, additional, Ordobás, María, additional, Martínez-Ochoa, Eva, additional, Fernández-Arribas, Socorro, additional, Lorusso, Nicola, additional, Martinez, Ana, additional, García-Fulgueiras, Ana, additional, Sastre-Palou, Bartolomé, additional, Losada-Castillo, Isabel, additional, Martínez-Cuenca, Silvia, additional, Águila, Mar Rodríguez-del, additional, Latorre-Millán, Miriam, additional, and Larrauri, Amparo, additional
- Published
- 2022
- Full Text
- View/download PDF
14. Protective Effect of Antiviral Treatment of Hospitalised Influenza Patients on the Risk of Death, EU 2010-2020
- Author
-
Adlhoch, Cornelia, primary, Delgado-Sanz, Concepción, additional, Carnahan, AnnaSara, additional, Larrauri, Amparo, additional, Popovici, Odette, additional, Bossuyt, Nathalie, additional, Thomas, Isabelle, additional, Kynčl, Jan, additional, Slezak, Pavel, additional, Brytting, Mia, additional, Guiomar, Raquel, additional, Redlberger-Fritz, Monika, additional, Melillo, Jackie M., additional, Melillo, Tanya, additional, Gageldonk-Lafeber, Arianne B., additional, Marbus, Sierk, additional, O'Donnell, Joan, additional, Domegan, Lisa, additional, and Olsen, Sonja, additional
- Published
- 2022
- Full Text
- View/download PDF
15. The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths
- Author
-
León-Gómez, Inmaculada, primary, Mazagatos, Clara, additional, Delgado-Sanz, Concepción, additional, Frías, Luz, additional, Vega-Piris, Lorena, additional, Rojas-Benedicto, Ayelén, additional, and Larrauri, Amparo, additional
- Published
- 2021
- Full Text
- View/download PDF
16. Initial assessment of the COVID-19 vaccination’s impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021
- Author
-
Nicolay, Nathalie, primary, Innocenti, Francesco, additional, Beauté, Julien, additional, Učakar, Veronika, additional, Grgič Vitek, Marta, additional, Poukka, Eero, additional, Hannila-Handelberg, Tuula, additional, Gauci, Charmaine, additional, Melillo, Tanya, additional, Georgakopoulou, Theano, additional, Jarkovsky, Jiri, additional, Slezak, Pavel, additional, Delgado-Sanz, Concepción, additional, Olmedo-Lucerón, Carmen, additional, Suija, Heleene, additional, Liausediene, Rasa, additional, O’Lorcain, Piaras, additional, Murphy, Niamh, additional, Peralta-Santos, André, additional, Casaca, Pedro, additional, Gregoriou, Ioanna, additional, Bundle, Nick, additional, Spiteri, Gianfranco, additional, and Ravasi, Giovanni, additional
- Published
- 2021
- Full Text
- View/download PDF
17. Assessing population-sampling strategies for reducing the COVID-19 incidence
- Author
-
Guzmán-Merino, Miguel, primary, Durán, Christian, additional, Marinescu, Maria-Cristina, additional, Delgado-Sanz, Concepción, additional, Gomez-Barroso, Diana, additional, Carretero, Jesus, additional, and Singh, David E., additional
- Published
- 2021
- Full Text
- View/download PDF
18. Evaluation of Vaccination Strategies for the metropolitan area of Madrid
- Author
-
Singh, David E., primary, Lucerón, Carmen Olmedo, additional, Sánchez, Aurora Limia, additional, Guzman-Merino, Miguel, additional, Duran, Christian, additional, Delgado-Sanz, Concepción, additional, Gomez-Barroso, Diana, additional, Carretero, Jesus, additional, and Marinescu, Maria-Cristina, additional
- Published
- 2021
- Full Text
- View/download PDF
19. COVID‐19 vaccine effectiveness against hospitalization due to SARS‐CoV‐2: A test‐negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain.
- Author
-
Mazagatos, Clara, Delgado‐Sanz, Concepción, Monge, Susana, Pozo, Francisco, Oliva, Jesús, Sandonis, Virginia, Gandarillas, Ana, Quiñones‐Rubio, Carmen, Ruiz‐Sopeña, Cristina, Gallardo‐García, Virtudes, Basile, Luca, Barranco‐Boada, María Isabel, Hidalgo‐Pardo, Olga, Vazquez‐Cancela, Olalla, García‐Vázquez, Miriam, Fernández‐Sierra, Amelia, Milagro‐Beamonte, Ana, Ordobás, María, Martínez‐Ochoa, Eva, and Fernández‐Arribas, Socorro
- Subjects
- *
VACCINE effectiveness , *SARS-CoV-2 Delta variant , *COVID-19 vaccines , *RESPIRATORY infections , *SARS-CoV-2 , *FLU vaccine efficacy - Abstract
Background: With the emergence of SARS‐CoV‐2, influenza surveillance systems in Spain were transformed into a new syndromic sentinel surveillance system. The Acute Respiratory Infection Surveillance System (SiVIRA in Spanish) is based on a sentinel network for acute respiratory infection (ARI) surveillance in primary care and a network of sentinel hospitals for severe ARI (SARI) surveillance in hospitals. Methods: Using a test‐negative design and data from SARI admissions notified to SiVIRA between January 1 and October 3, 2021, we estimated COVID‐19 vaccine effectiveness (VE) against hospitalization, by age group, vaccine type, time since vaccination, and SARS‐CoV‐2 variant. Results: VE was 89% (95% CI: 83–93) against COVID‐19 hospitalization overall in persons aged 20 years and older. VE was higher for mRNA vaccines, and lower for those aged 80 years and older, with a decrease in protection beyond 3 months of completing vaccination, and a further decrease after 5 months. We found no differences between periods with circulation of Alpha or Delta SARS‐CoV‐2 variants, although variant‐specific VE was slightly higher against Alpha. Conclusions: The SiVIRA sentinel hospital surveillance network in Spain was able to describe clinical and epidemiological characteristics of SARI hospitalizations and provide estimates of COVID‐19 VE in the population under surveillance. Our estimates add to evidence of high effectiveness of mRNA vaccines against severe COVID‐19 and waning of protection with time since vaccination in those aged 80 or older. No substantial differences were observed between SARS‐CoV‐2 variants (Alpha vs. Delta). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
- Author
-
Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020
- Subjects
Infecções Respiratórias ,Adult ,Test-negative design ,2019-20 coronavirus outbreak ,Pediatrics ,medicine.medical_specialty ,RM ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,[SDV]Life Sciences [q-bio] ,Primary health care ,Primary care ,030204 cardiovascular system & hematology ,Multicentre study ,03 medical and health sciences ,Elderly ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,RA0421 ,RA0421 Public health. Hygiene. Preventive Medicine ,Virology ,Medicine ,Humans ,030212 general & internal medicine ,Aged ,Vaccine effectiveness ,QR355 ,vaccine effectiveness ,Primary Health Care ,business.industry ,SARS-CoV-2 ,Efetividade da vacina contra COVID-19 ,test-negative design ,Public Health, Environmental and Occupational Health ,COVID-19 ,3rd-DAS ,NIS ,Estados de Saúde e de Doença ,multicentre study ,3. Good health ,RM Therapeutics. Pharmacology ,Vaccination ,Europe ,Determinantes da Saúde e da Doença ,business ,QR355 Virology ,Rapid Communication - Abstract
I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion
- Published
- 2021
21. Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries
- Author
-
Staadegaard, Lisa, primary, Caini, Saverio, additional, Wangchuk, Sonam, additional, Thapa, Binay, additional, Almeida, Walquiria Aparecida Ferreira, additional, Carvalho, Felipe Cotrim, additional, Fasce, Rodrigo A., additional, Bustos, Patricia, additional, Kyncl, Jan, additional, Novakova, Ludmila, additional, Caicedo, Alfredo Bruno, additional, Mora Coloma, Domenica Joseth, additional, Meijer, Adam, additional, Hooiveld, Mariëtte, additional, Huang, Q. Sue, additional, Wood, Tim, additional, Guiomar, Raquel, additional, Rodrigues, Ana Paula, additional, Lee, Vernon Jian Ming, additional, Ang, Li Wei, additional, Cohen, Cheryl, additional, Moyes, Jocelyn, additional, Larrauri, Amparo, additional, Delgado‐Sanz, Concepción, additional, Demont, Clarisse, additional, Bangert, Mathieu, additional, Dückers, Michel, additional, Summeren, Jojanneke, additional, and Paget, John, additional
- Published
- 2021
- Full Text
- View/download PDF
22. Data management in epiGraph COVID-19 epidemic simulator
- Author
-
Guzmán Merino, Miguel, Duran Gonzalez, Christian, Marinescu, María Cristina, Delgado Sanz, Concepción, Gómez Barroso, Diana, Carretero Pérez, Jesús, Expósito Singh, David, and European Commission
- Subjects
Informática ,epidemiological simulation ,COVID-19 ,heterogeneous ,parallel tool ,data processing - Abstract
The transmission of COVID-19 through a population depends on many factors which model, incorporate, and integrate a large number of heterogeneous data sources. The work we describe in this paper focuses on the data management aspect of EpiGraph, a scalable agent-based virus-propagation simulator. We describe the data acquisition and pre-processing tasks that are necessary to map the data to the different models implemented in EpiGraph in a way that is efficient and comprehensible. We also report on post-processing, analysis, and visualization of the outputs, tasks that are fundamental to make the simulation results useful for the final users. Our simulator captures complex interactions between social processes, virus characteristics, travel patterns, climate, vaccination, and non-pharmaceutical interventions. We end by demonstrating the entire pipeline with one evaluation for Spain for the third COVID wave starting on December 27th of 2020. This work has been supported by the Spanish Instituto de Salud Carlos III under the project grant 2020/00183/001, the project grant BCV-2021-1-0011, of the Spanish Supercomputing Network (RES) and the European Union's Horizon 2020 JTI-EuroHPC research and innovation program under grant agreement No 956748.
- Published
- 2021
23. Assessing population-sampling strategies for reducing the COVID-19 incidence
- Author
-
Universitat Politècnica de Catalunya. Departament d'Arquitectura de Computadors, Barcelona Supercomputing Center, Guzmán Merino, Miguel, Durán, Christian, Marinescu, Maria Cristina, Delgado Sanz, Concepción, Gómez Barroso, Diana, Carretero Pérez, Jesús, Singh, David E., Universitat Politècnica de Catalunya. Departament d'Arquitectura de Computadors, Barcelona Supercomputing Center, Guzmán Merino, Miguel, Durán, Christian, Marinescu, Maria Cristina, Delgado Sanz, Concepción, Gómez Barroso, Diana, Carretero Pérez, Jesús, and Singh, David E.
- Abstract
As long as critical levels of vaccination have not been reached to ensure heard immunity, and new SARS-CoV-2 strains are developing, the only realistic way to reduce the infection speed in a population is to track the infected individuals before they pass on the virus. Testing the population via sampling has shown good results in slowing the epidemic spread. Sampling can be implemented at different times during the epidemic and may be done either per individual or for combined groups of people at a time. The work we present here makes two main contributions. We first extend and refine our scalable agent-based COVID-19 simulator to incorporate an improved socio-demographic model which considers professions, as well as a more realistic population mixing model based on contact matrices per country. These extensions are necessary to develop and test various sampling strategies in a scenario including the 62 largest cities in Spain; this is our second contribution. As part of the evaluation, we also analyze the impact of different parameters, such as testing frequency, quarantine time, percentage of quarantine breakers, or group testing, on sampling efficacy. Our results show that the most effective strategies are pooling, rapid antigen test campaigns, and requiring negative testing for access to public areas. The effectiveness of all these strategies can be greatly increased by reducing the number of contacts for infected individual., This work has been supported by the Carlos III Institute of Health under the project grant 2020/00183/001, the project grant BCV-2021-1-0011, of the Spanish Supercomputing Network (RES) and the European Union’s Horizon 2020 JTI-EuroHPC research and innovation program under grant agreement No 956748. The role of all study sponsors was limited to financial support and did not imply participation of any kind in the study and collection, analysis, and interpretation of data, nor in the writing of the manuscript., Peer Reviewed, Postprint (published version)
- Published
- 2021
24. Simulation of COVID-19 propagation scenarios in the Madrid metropolitan area
- Author
-
Universitat Politècnica de Catalunya. Departament d'Arquitectura de Computadors, Barcelona Supercomputing Center, Singh, David E., Marinescu, Maria Cristina, Guzmán Merino, Miguel, Durán, Christian, Delgado Sanz, Concepción, Gómez Barroso, Diana, Carretero Pérez, Jesús, Universitat Politècnica de Catalunya. Departament d'Arquitectura de Computadors, Barcelona Supercomputing Center, Singh, David E., Marinescu, Maria Cristina, Guzmán Merino, Miguel, Durán, Christian, Delgado Sanz, Concepción, Gómez Barroso, Diana, and Carretero Pérez, Jesús
- Abstract
This work presents simulation results for different mitigation and confinement scenarios for the propagation of COVID-19 in the metropolitan area of Madrid. These scenarios were implemented and tested using EpiGraph, an epidemic simulator which has been extended to simulate COVID-19 propagation. EpiGraph implements a social interaction model, which realistically captures a large number of characteristics of individuals and groups, as well as their individual interconnections, which are extracted from connection patterns in social networks. Besides the epidemiological and social interaction components, it also models people's short and long-distance movements as part of a transportation model. These features, together with the capacity to simulate scenarios with millions of individuals and apply different contention and mitigation measures, gives EpiGraph the potential to reproduce the COVID-19 evolution and study medium-term effects of the virus when applying mitigation methods. EpiGraph, obtains closely aligned infected and death curves related to the first wave in the Madrid metropolitan area, achieving similar seroprevalence values. We also show that selective lockdown for people over 60 would reduce the number of deaths. In addition, evaluate the effect of the use of face masks after the first wave, which shows that the percentage of people that comply with mask use is a crucial factor for mitigating the infection's spread., This work has been supported by the Spanish Instituto de Salud Carlos III under the project grant 2020/00183/001 Medium and long-term forecast of the spread of COVID-19, the project grant BCV-2020-3-0008 Simulating COVID-19 propagation at a European-level of the Spanish Supercomputing Network (RES), and the EU project ‘ASPIDE: Exascale Programming Models for Extreme Data Processing under grant 801091., Peer Reviewed, Postprint (published version)
- Published
- 2021
25. The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries
- Author
-
Staadegaard, Lisa, primary, Caini, Saverio, additional, Wangchuk, Sonam, additional, Thapa, Binay, additional, de Almeida, Walquiria Aparecida Ferreira, additional, de Carvalho, Felipe Cotrim, additional, Njouom, Richard, additional, Fasce, Rodrigo A, additional, Bustos, Patricia, additional, Kyncl, Jan, additional, Novakova, Ludmila, additional, Caicedo, Alfredo Bruno, additional, de Mora Coloma, Domenica Joseth, additional, Meijer, Adam, additional, Hooiveld, Mariëtte, additional, Huang, Sue, additional, Wood, Tim, additional, Guiomar, Raquel, additional, Rodrigues, Ana Paula, additional, Danilenko, Daria, additional, Stolyarov, Kirill, additional, Lee, Vernon Jian Ming, additional, Ang, Li Wei, additional, Cohen, Cheryl, additional, Moyes, Jocelyn, additional, Larrauri, Amparo, additional, Delgado-Sanz, Concepción, additional, Le, Mai Quynh, additional, Hoang, Phuong Vu Mai, additional, Demont, Clarisse, additional, Bangert, Mathieu, additional, van Summeren, Jojanneke, additional, Dückers, Michel, additional, and Paget, John, additional
- Published
- 2021
- Full Text
- View/download PDF
26. Simulation of COVID-19 Propagation Scenarios in the Madrid Metropolitan Area
- Author
-
Singh, David E., primary, Marinescu, Maria-Cristina, additional, Guzmán-Merino, Miguel, additional, Durán, Christian, additional, Delgado-Sanz, Concepción, additional, Gomez-Barroso, Diana, additional, and Carretero, Jesus, additional
- Published
- 2021
- Full Text
- View/download PDF
27. Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020
- Author
-
Vestergaard, Lasse S, Nielsen, Jens, Richter, Lukas, Schmid, Daniela, Bustos, Natalia, Braeye, Toon, Denissov, Gleb, Veideman, Tatjana, Luomala, Oskari, Möttönen, Teemu, Fouillet, Anne, Caserio-Schönemann, Céline, an der Heiden, Matthias, Uphoff, Helmut, Lytras, Theodore, Gkolfinopoulou, Kassiani, Paldy, Anna, Domegan, Lisa, O'Donnell, Joan, de’ Donato, Francesca, Noccioli, Fiammetta, Hoffmann, Patrick, Velez, Telma, England, Kathleen, van Asten, Liselotte, White, Richard A, Tønnessen, Ragnhild, da Silva, Susana P, Rodrigues, Ana P, Larrauri, Amparo, Delgado-Sanz, Concepción, Farah, Ahmed, Galanis, Ilias, Junker, Christoph, Perisa, Damir, Sinnathamby, Mary, Andrews, Nick, O'Doherty, Mark, Marquess, Diogo FP, Kennedy, Sharon, Olsen, Sonja J, Pebody, Richard, Krause, Tyra G, Mølbak, Kåre, Penttinen, Pasi, Bundle, Nick, Adlhoch, Cornelia, and European Centre for Disease Prevention and Control (ECDC)
- Subjects
Male ,COVID-19 Pandemic ,All-cause Mortality ,Epidemiology ,Covid-19 pandemic ,Disease Outbreaks ,Cause of Death ,Pandemic ,Medicine ,Child ,Excess mortality ,Aged, 80 and over ,Middle Aged ,All-cause mortality ,Europe ,Child, Preschool ,Population Surveillance ,Female ,Coronavirus Infections ,Rapid Communication ,EuroMOMO ,Preliminary Data ,Adult ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Adolescent ,Pneumonia, Viral ,Betacoronavirus ,Young Adult ,Age Distribution ,Virology ,Influenza, Human ,Humans ,Mortality ,Pandemics ,Aged ,Portugal ,business.industry ,SARS-CoV-2 ,Public health ,Public Health, Environmental and Occupational Health ,Infant, Newborn ,COVID-19 ,Infant ,Estados de Saúde e de Doença ,Coronavirus ,business ,Sistema de Vigilância ,All cause mortality ,Demography - Abstract
A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March-April 2020. Excess mortality particularly affected ≥ 65 year olds (91% of all excess deaths), but also 45-64 (8%) and 15-44 year olds (1%). No excess mortality was observed in 0-14 year olds. he EuroMOMO network has received financial support from the European Centre for Disease Prevention and Control (ECDC) and from the World Health Organization (WHO) Regional Office for Europe. We acknowledge all EuroMOMO partners for their contributions as well as the various National Offices of Statistics that are essential partners in ensuring the ongoing monitoring of mortality across Europe. Sí
- Published
- 2020
28. Resultados de la Vigilancia Epidemiológica de las enfermedades transmisibles. Informe anual. 2017-2018
- Author
-
Amillategui, Rocio, Cano-Portero, Rosa, Almazan-Isla, Javier, Boix Martinez, Raquel, Delgado-Sanz, Concepción, Diaz Garcia, Maria Oliva, Diaz-Franco, Asuncion, Fernandez Martinez, Beatriz, Larrauri, Amparo, López-Perea, Noemí, Lucas Herraiz, Paloma, Martin-Mesonero, Carmen, Martinez-Sanchez, Elena Vanesa, Masa-Calles, Josefa, Oliva Dominguez, Jesus Angel, Padron-Monedero, Alicia, Ruiz-Alguero, Marta, Torres-de Mier, Maria Viarce, and Varela Martinez, Maria del Carmen
- Subjects
Enfermedades transmisibles ,Vigilancia epidemiológica - Abstract
El objetivo final de la vigilancia de las enfermedades transmisibles es reducir su incidencia en la comunidad. La Red Nacional de Vigilancia Epidemiológica (RENAVE) tiene entre sus funciones la recogida sistemática de la información epidemiológica, su análisis e interpretación y la difusión de los resultados1. Este informe presenta los resultados de la vigilancia de las enfermedades transmisibles para los años 2017 y 2018 realizada por los servicios de vigilancia de las comunidades autónomas (CCAA). El Centro de Coordinación de Alertas y Emergencias (CCAES) del Ministerio de Sanidad coordina a las CCAA para llevar a cabo esta actividad y la gestión de la información la realiza el Centro Nacional de Epidemiología del Instituto de Salud Carlos III de acuerdo a los protocolos de la RENAVE. Agradecimientos Abreviatruras y Acrónimos usados en este informe. 1. Introducción 2. Vigilancia de las enfermedades infecciosas en 2017-2018. 3. Enfermedades transmitidas por alimentos y agua 4. Enfermedades prevenibles por la vacunación.5. Enfermedades de transmisión respiratoria 6. Enfermedades transmitidas por vectores 7. Zoonosis 8. Enfermedades de transmisión sexual y parenteral 9. Encefalopatías espongiformes transmisibles humanas. 10. Anexos No
- Published
- 2020
29. Evaluating the impact of the weather conditions on the influenza propagation
- Author
-
Universitat Politècnica de Catalunya. Departament d'Arquitectura de Computadors, Barcelona Supercomputing Center, Singh, David E., Marinescu, Maria Cristina, Carretero Pérez, Jesús, Delgado Sanz, Concepción, Gómez Barroso, Diana, Larrauri Cámara, Amparo, Universitat Politècnica de Catalunya. Departament d'Arquitectura de Computadors, Barcelona Supercomputing Center, Singh, David E., Marinescu, Maria Cristina, Carretero Pérez, Jesús, Delgado Sanz, Concepción, Gómez Barroso, Diana, and Larrauri Cámara, Amparo
- Abstract
Background: Predicting the details of how an epidemic evolves is highly valuable as health institutions need to better plan towards limiting the infection propagation effects and optimizing their prediction and response capabilities. Simulation is a cost- and time-effective way of predicting the evolution of the infection as the joint influence of many different factors: interaction patterns, personal characteristics, travel patterns, meteorological conditions, previous vaccination, etc. The work presented in this paper extends EpiGraph, our influenza epidemic simulator, by introducing a meteorological model as a modular component that interacts with the rest of EpiGraph’s modules to refine our previous simulation results. Our goal is to estimate the effects of changes in temperature and relative humidity on the patterns of epidemic influenza based on data provided by the Spanish Influenza Sentinel Surveillance System (SISSS) and the Spanish Meteorological Agency (AEMET). Methods: Our meteorological model is based on the regression model developed by AB and JS, and it is tuned with influenza surveillance data obtained from SISSS. After pre-processing this data to clean it and reconstruct missing samples, we obtain new values for the reproduction number of each urban region in Spain, every 10 minutes during 2011. We simulate the propagation of the influenza by setting the date of the epidemic onset and the initial influenza-illness rates for each urban region. Results: We show that the simulation results have the same propagation shape as the weekly influenza rates as recorded by SISSS. We perform experiments for a realistic scenario based on actual meteorological data from 2010-2011, and for synthetic values assumed under simplified predicted climate change conditions. Results show that a diminishing relative humidity of 10% produces an increment of about 1.6% in the final infection rate. The effect of temperature changes on the infection spread is also noticeable, This work has been partially supported by the Spanish “Ministerio de Economía y Competitividad” under the project grant TIN2016-79637-P “Towards Unification of HPC and Big Data paradigms”. The work of Maria-Cristina Marinescu has been partially supported by the H2020 European project GrowSmarter under project grant ref. 646456., Peer Reviewed, Postprint (published version)
- Published
- 2020
30. Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020
- Author
-
Vestergaard, Lasse S., Nielsen, Jens, Richter, Lukas, Schmid, Daniela, Bustos, Natalia, Braeye, Toon, Denissov, Gleb, Veideman, Tatjana, Luomala, Oskari, Möttönen, Teemu, Fouillet, Anne, Caserio-Schönemann, Céline, der Heiden, Matthias an, Uphoff, Helmut, Lytras, Theodore, Gkolfinopoulou, Kassiani, Paldy, Anna, Domegan, Lisa, O’Donnell, Joan, de’ Donato, Francesca, Noccioli, Fiammetta, Hoffmann, Patrick, Velez, Telma, England, Kathleen, van Asten, Liselotte, White, Richard A., Tønnessen, Ragnhild, da Silva, Susana P., Rodrigues, Ana P., Larrauri, Amparo, Delgado-Sanz, Concepción, Farah, Ahmed, Galanis, Ilias, Junker, Christoph, Perisa, Damir, Sinnathamby, Mary, Andrews, Nick, O’Doherty, Mark, Marquess, Diogo F.P., Kennedy, Sharon, Olsen, Sonja J., Pebody, Richard, Krause, Tyra G., Mølbak, Kåre, Vestergaard, Lasse S., Nielsen, Jens, Richter, Lukas, Schmid, Daniela, Bustos, Natalia, Braeye, Toon, Denissov, Gleb, Veideman, Tatjana, Luomala, Oskari, Möttönen, Teemu, Fouillet, Anne, Caserio-Schönemann, Céline, der Heiden, Matthias an, Uphoff, Helmut, Lytras, Theodore, Gkolfinopoulou, Kassiani, Paldy, Anna, Domegan, Lisa, O’Donnell, Joan, de’ Donato, Francesca, Noccioli, Fiammetta, Hoffmann, Patrick, Velez, Telma, England, Kathleen, van Asten, Liselotte, White, Richard A., Tønnessen, Ragnhild, da Silva, Susana P., Rodrigues, Ana P., Larrauri, Amparo, Delgado-Sanz, Concepción, Farah, Ahmed, Galanis, Ilias, Junker, Christoph, Perisa, Damir, Sinnathamby, Mary, Andrews, Nick, O’Doherty, Mark, Marquess, Diogo F.P., Kennedy, Sharon, Olsen, Sonja J., Pebody, Richard, Krause, Tyra G., and Mølbak, Kåre
- Abstract
A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March–April 2020. Excess mortality particularly affected ≥ 65 year olds (91% of all excess deaths), but also 45–64 (8%) and 15–44 year olds (1%). No excess mortality was observed in 0–14 year olds.
- Published
- 2020
31. COVID-19 outbreaks in a transmission control scenario: challenges posed by social and leisure activities, and for workers in vulnerable conditions, Spain, early summer 2020
- Author
-
Guzmán Herrador, Bernardo R., Rivera Ariza, Silvia, Latasa Zamalloa, Pello, Chong Valbuena, Andrea, Pachés, Paula Julián, Monge, Susana, García San Miguel, Lucía, Pérez Olaso, Oscar, Sánchez Sagrado, Teresa, Pichler, Alexander, Suárez Rodríguez, Berta, Sierra Moros, María José, Simón Soria, Fernando, García Gómez, Montserrat, Varela Martínez, Carmen, Delgado Sanz, Concepción, Amillategui Dos Santos, Rocío, Lorusso, Nicola, Carmona Ubago, Alberto, Durán Pla, Enric, Fernández Jiménez, Cristina, García Vázquez, Miriam, Cebollada Gracia, Ana Delia, Boone, An LD, Fernández Ibáñez, Ana, Álvarez Fernández, Blanca, Giménez Durán, Jaume, Caffaro Rovira, Mercedes, Salom Castell, Magdalena, Rojo Moreno, Magdalena Lucía, Pla Francés, Alicia, Viloria Raymundo, Luis, Curiel-Olmo, Soraya, Galán Cuesta, Manuel, Jané, Mireia, Martínez Gil, Ana, Izquierdo, Conchita, Rivas Pérez, Ana Isabel, Ramos Marín, Violeta, López Corrales, Irene, Rodolfo Saavedra, Remedios, Ruíz Pérez, María José, García Hernández, Sara, García-López, María, Marcos Rodríguez, María del Henar, Ruíz Sopeña, Cristina, Rodríguez Arévalo, Olga Lucía, Blasco Guillem, Sonia, Taberner Cuevas, Ana, López-Tercero Torvisco, María del Mar, Salete, Cristina Andreu, Montaño González, Belén, González Villar, Ana Isabel, Pérez Martínez, Olaia, Losada Castillo, Isabel, Rodero Garduño, Inmaculada, Sánchez Diaz, Jesús, Jiménez Bueno, Susana, Castrillejo Pérez, Daniel, Hermoso Castro, Luisa F., Gómez Anés, Atanasio A., García-Fulgueiras. Ana, Chirlaque, Maria Dolores, Barranco, M. Isabel, García Cenoz, Manuel, Sayón-Orea, Carmen, Casado, Itziar, Oribe Amores, Madalen, Mokoroa Carollo, Olatz, Ibáñez Pérez, Ana Carmen, Martínez Ochoa, Eva, Martínez Zárate, María Puy, Guzmán Herrador, Bernardo R., Rivera Ariza, Silvia, Latasa Zamalloa, Pello, Chong Valbuena, Andrea, Pachés, Paula Julián, Monge, Susana, García San Miguel, Lucía, Pérez Olaso, Oscar, Sánchez Sagrado, Teresa, Pichler, Alexander, Suárez Rodríguez, Berta, Sierra Moros, María José, Simón Soria, Fernando, García Gómez, Montserrat, Varela Martínez, Carmen, Delgado Sanz, Concepción, Amillategui Dos Santos, Rocío, Lorusso, Nicola, Carmona Ubago, Alberto, Durán Pla, Enric, Fernández Jiménez, Cristina, García Vázquez, Miriam, Cebollada Gracia, Ana Delia, Boone, An LD, Fernández Ibáñez, Ana, Álvarez Fernández, Blanca, Giménez Durán, Jaume, Caffaro Rovira, Mercedes, Salom Castell, Magdalena, Rojo Moreno, Magdalena Lucía, Pla Francés, Alicia, Viloria Raymundo, Luis, Curiel-Olmo, Soraya, Galán Cuesta, Manuel, Jané, Mireia, Martínez Gil, Ana, Izquierdo, Conchita, Rivas Pérez, Ana Isabel, Ramos Marín, Violeta, López Corrales, Irene, Rodolfo Saavedra, Remedios, Ruíz Pérez, María José, García Hernández, Sara, García-López, María, Marcos Rodríguez, María del Henar, Ruíz Sopeña, Cristina, Rodríguez Arévalo, Olga Lucía, Blasco Guillem, Sonia, Taberner Cuevas, Ana, López-Tercero Torvisco, María del Mar, Salete, Cristina Andreu, Montaño González, Belén, González Villar, Ana Isabel, Pérez Martínez, Olaia, Losada Castillo, Isabel, Rodero Garduño, Inmaculada, Sánchez Diaz, Jesús, Jiménez Bueno, Susana, Castrillejo Pérez, Daniel, Hermoso Castro, Luisa F., Gómez Anés, Atanasio A., García-Fulgueiras. Ana, Chirlaque, Maria Dolores, Barranco, M. Isabel, García Cenoz, Manuel, Sayón-Orea, Carmen, Casado, Itziar, Oribe Amores, Madalen, Mokoroa Carollo, Olatz, Ibáñez Pérez, Ana Carmen, Martínez Ochoa, Eva, and Martínez Zárate, María Puy
- Abstract
Severe acute respiratory syndrome coronavirus 2 community-wide transmission declined in Spain by early May 2020, being replaced by outbreaks and sporadic cases. From mid-June to 2 August, excluding single household outbreaks, 673 outbreaks were notified nationally, 551 active (>6,200 cases) at the time. More than half of these outbreaks and cases coincided with: (i) social (family/friends’ gatherings or leisure venues) and (ii) occupational (mainly involving workers in vulnerable conditions) settings. Control measures were accordingly applied.
- Published
- 2020
32. Effectiveness of influenza vaccination during pregnancy to prevent severe infection in children under 6 months of age, Spain, 2017–2019
- Author
-
Mazagatos, Clara, primary, Godoy, Pere, additional, Muñoz Almagro, Carmen, additional, Pozo, Francisco, additional, Larrauri, A, additional, Gallardo García, Virtudes, additional, López Hernández, Begoña, additional, García, Miriam, additional, Huerta González, Ismael, additional, Giménez Duran, Jaume, additional, Falcón García, Isabel, additional, Ángel Núñez Gallo, Domingo, additional, Viloria Raymundo, Luis, additional, Gutiérrez, Gonzalo, additional, Torner Gracia, Nuria, additional, Villatoro Bongiorno, Katja, additional, Javier Roig Sena, Francisco, additional, García Comas, Luis, additional, Isabel Barranco Boada, María, additional, Castilla Catalán, Jesús, additional, Etxebarriarteun Aranzabal, Larraitz, additional, Beraza Ortiz, Xabier, additional, Quiñones, Carmen, additional, Martínez Ochoa, Eva, additional, Rivas, Ana, additional, Castrillejo Pérez, Daniel, additional, Delgado-Sanz, Concepción, additional, Oliva, Jesús, additional, Gherasim, Alin, additional, and Gallego Berciano, Pilar, additional
- Published
- 2020
- Full Text
- View/download PDF
33. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study
- Author
-
Pastor-Barriuso, Roberto, primary, Pérez-Gómez, Beatriz, additional, Hernán, Miguel A, additional, Pérez-Olmeda, Mayte, additional, Yotti, Raquel, additional, Oteo-Iglesias, Jesús, additional, Sanmartín, Jose L, additional, León-Gómez, Inmaculada, additional, Fernández-García, Aurora, additional, Fernández-Navarro, Pablo, additional, Cruz, Israel, additional, Martín, Mariano, additional, Delgado-Sanz, Concepción, additional, Fernández de Larrea, Nerea, additional, León Paniagua, Jose, additional, Muñoz-Montalvo, Juan F, additional, Blanco, Faustino, additional, Larrauri, Amparo, additional, and Pollán, Marina, additional
- Published
- 2020
- Full Text
- View/download PDF
34. Illness Severity in Hospitalized Influenza Patients by Virus Type and Subtype, Spain, 2010–2017
- Author
-
Delgado-Sanz, Concepción, primary, Mazagatos-Ateca, Clara, additional, Oliva, Jesús, additional, Gherasim, Alin, additional, and Larrauri, Amparo, additional
- Published
- 2020
- Full Text
- View/download PDF
35. The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries
- Author
-
Staadegaard, Lisa, primary, Caini, Saverio, additional, Wangchuk, Sonam, additional, Thapa, Binay, additional, Ferreira de Almeida, Walquiria Aparecida, additional, Cotrim de Carvalho, Felipe, additional, Njouom, Richard, additional, Fasce, Rodrigo A., additional, Bustos, Patricia, additional, Kyncl, Jan, additional, Novakova, Ludmila, additional, Caicedo, Alfredo Bruno, additional, Joseth de Mora Coloma, Domenica, additional, Meijer, Adam, additional, Hooiveld, Mariëtte, additional, Huang, Sue, additional, Wood, Tim, additional, Guiomar, Raquel, additional, Rodrigues, Ana Paula, additional, Danilenko, Daria, additional, Stolyarov, Kirill, additional, Lee, Vernon J., additional, Ang, Li Wei, additional, Cohen, Cheryl, additional, Moyes, Jocelyn, additional, Larrauri, Amparo, additional, Delgado-Sanz, Concepción, additional, Le, Mai Quynh, additional, Hoang, Phuong Vu Mai, additional, Demont, Clarisse, additional, Bangert, Mathieu, additional, van Summeren, Jojanneke, additional, Dückers, Michel, additional, and Paget, John, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Informe de situación: Actividad gripal en la temporada 2018-19 Evaluación de riesgo hasta semana 03/2019
- Author
-
Oliva, Jesus, Delgado Sanz, Concepción, Gherasim, Alin, Pozo, Francisco, Casas, Inmaculada, Larrauri, Amparo, and Gripe en España, El Sistema de Vigilancia de
- Subjects
vacunación antigripal ,Gripe ,vigilancia de la gripe en España ,temporada - Abstract
[ES] La epidemia gripal 2018-19 se ha iniciado en España en la semana 01/2019, tres semanas más tarde que en las dos temporadas previas, pero en el rango de las temporadas post-pandémicas previas. La incidencia de gripe se asocia de forma casi exclusiva a la circulación de virus de la gripe tipo A. Aunque la proporción entre subtipos A(H1N1)pdm09 y A(H3N2) es similar, la tendencia de las últimas semanas indica un aumento en la proporción del primero. Los datos de vigilancia en hospitales señalan una distribución similar por tipo/subtipo de virus. Si bien el grupo de mayores de 65 años es el mayoritario (53%), este porcentaje es inferior al que se puede observar en aquellas temporadas en las que predomina A(H3N2) y se parece más a aquellas temporadas en las que predominó A(H1N1)pdm09. Hasta el momento, la epidemia gripal 2018-19 presenta un nivel bajo de transmisibilidad en todos los grupos de edad. El impacto ocasionado en la población española se estima medio, en términos de tasa de hospitalización y bajo en términos de excesos de mortalidad por todas las causas. Ambos indicadores, así como la gravedad clínica de la enfermedad, se seguirán evaluando en las semanas próximas de la epidemia gripal. Las estimaciones preliminares de EV antigripal de esta temporada en Canadá señalan un valor de EV frente a A(H1N1)pdm09 por encima del 70%, en consonancia con datos preliminares de la red Europea I-MOVE. La EV antigripal frente a A(H3N2) es subóptima hasta el momento. Sin embargo, se han estimado valores moderados de EV antigripal frente a todos los virus A en grupos recomendados de vacunación, lo que refuerza la recomendación oficial de vacunación antigripal en estos grupos de riesgo de complicaciones por gripe. En definitiva, las características de la epidemia 2018-19 hasta el momento se mueven en un patrón intermedio entre las temporadas de A(H1N1)pdm09 y las de A(H3N2), de forma que según derive la circulación mayoritaria de uno u otro virus, cabe esperar que predominen unas u otras características. [EN] Influenza activity in Spain started this 2018-19 season in week 01/2019, three weeks later than in the previous two seasons, but in the range of the previous post-pandemic seasons. So far, the influenza season 2018-19 is characterized by the predominant circulation of type A. Although both A(H1N1) pdm09 and A(H3N2) subtypes are co-circulating in similar proportions, the trend of the last weeks indicates an increase in the proportion of the first. Surveillance data in hospitals indicate a similar distribution by type/subtype. Although 53% were adults 65 years of age and older, this percentage is lower than that observed in seasons associated with A(H3N2) predominance, and more similar to those seasons in which A(H1N1)pdm09 predominated. So far, the influenza season 2018-19 has a low level of transmissibility in all age groups. The impact caused in the Spanish population is estimated as “medium”, in terms of hospitalization rates, and “low” in terms of all causes excess mortality. Both indicators, as well as the clinical severity of the disease, will continue to be evaluated in the next few weeks of the flu epidemic. Preliminary estimates of the effectiveness of influenza vaccine this season in Canada indicate good vaccine effectiveness (VE) (above 70%), in line with preliminary data from the European I-MOVE network. The VE against influenza A(H3N2) viruses is suboptimal so far. However, moderate values of VE have been estimated against all A viruses in recommended groups of vaccination, which reinforces the official recommendation of influenza vaccination in these risk groups of complications due to influenza. In short, the characteristics of the influenza season 2018-19 so far move in an intermediate pattern between the A(H1N1)pdm09 seasons and those with A(H3N2) predominance. It is expected that some or other characteristics will prevail depending on the predominance of the circulation of one or the other virus.
- Published
- 2019
37. Gravedad de la epidemia gripal 2017-18 en España
- Author
-
Oliva, Jesús, Delgado Sanz, Concepción, Mazagatos, Clara, and Larrauri, Amparo
- Subjects
epidemia ,Gripe ,España - Abstract
[ES] Siguiendo las recomendaciones de la Organización Mundial de la Salud (OMS), España ha adaptado su guía PISA (por las siglas en inglés de Pandemic Influenza Severity Assessment) para evaluar la gravedad de cualquier epidemia de gripe, estacional o pandémica, a partir de la información de vigilancia de gripe disponible. Dicha gravedad se establece en función de tres indicadores: la transmisibilidad del virus circulante, la gravedad clínica de la enfermedad que produce y su impacto en la población. En este manuscrito se aplican los indicadores y parámetros PISA utilizados en España con la información obtenida en el Sistema de Vigilancia de Gripe en España (SVGE) y del sistema de monitorización de la mortalidad diaria (MoMo y EuroMOMO), con el objetivo de evaluar la gravedad de la gripe durante la temporada 2017-18 en España. La transmisibilidad de la epidemia gripal de la temporada 2017-18 alcanzó un nivel moderado/alto para todas las edades en la semana de máxima actividad gripal (3/2018), y se caracterizó particularmente por una alta transmisibilidad en mayores de 64 años. En cuanto a la gravedad clínica, la epidemia gripal 2017-18, según el grado de admisión en UCI entre los casos graves hospitalizados confirmados de gripe (CGHCG), presentó un nivel bajo para todas las edades, adultos jóvenes y mayores de 64 años. En menores de 15 años el porcentaje de admisión en UCI alcanzó niveles altos respecto a los valores observados en temporadas previas. En términos de letalidad entre los CGHCG, se estimó que en la temporada 2017-18 se alcanzó un nivel alto de gravedad clínica en todas las edades y mayores de 64 años. En adultos jóvenes de 15-64 años la letalidad se estabilizó en un nivel bajo en el pico de la epidemia gripal y en menores de 15 años se consideró baja respecto a los valores observados en temporadas previas. En cuanto al impacto, la temporada 2017-18 presentó un impacto muy alto en términos de tasas de hospitalización de CGHCG en todas las edades, a expensas fundamentalmente de las hospitalizaciones por gripe en el grupo de mayores de 64 años. En este grupo de edad se observaron las tasas más altas de hospitalización desde la temporada 2013-14. En términos de excesos de mortalidad por todas las causas, la epidemia alcanzó un impacto alto en todas las edades, a expensas fundamentalmente de la mortalidad observada en el grupo de mayores de 64 años, siendo, en menores de 15 años y adultos jóvenes, el impacto nulo. En definitiva, la guía PISA permite la estimación de una serie de indicadores y parámetros para evaluar la gravedad de una epidemia o posible pandemia de gripe. La actividad realizada en el marco del proyecto PISA es un proceso dinámico en continua revisión, susceptible de mejora a medida que se desarrolla y aplica a las diferentes temporadas de gripe. [EN] Following World Health Organization (WHO) recommendations, Spain has adapted its PISA guide (for Pandemic Influenza Severity Assessment) to assess the severity in seasonal epidemics and pandemics, based on available influenza surveillance information. This severity is defined in terms of three indicators: the transmissibility of the circulating virus, the seriousness or clinical severity of the disease it produces and its impact on the population. In this manuscript the PISA indicators and parameters used in Spain are applied with the information obtained in the Spanish Influenza Surveillance System and the daily mortality monitoring system (MoMo and EuroMOMO), with the objective of evaluating the severity of the influenza during the 2017-18 season in Spain. The transmissibility indicator in the 2017-18 influenza season reached a moderate / high level for all ages in the peak week (week 03/2018), and was particularly high in people over 64 years. Regarding seriousness, the 2017-18 influenza epidemic, according to the cumulative percentage of ICU admissions among severe hospitalized confirmed influenza cases (SHCIC), presented a low level for all ages, young adults and those over 64 years. In children under 15, the cumulative percentage of ICU admissions reached high levels compared to the values observed in previous seasons. In terms of lethality among the SHCIC, it was estimated that the 2017-18 season presented a high level of clinical severity at all ages and over 64 years. In young adults aged 15-64, lethality stabilized at a low level at the peak of the flu epidemic. In children under 15 years, the lethality was estimated low compared to the values observed in previous seasons. Regarding the impact, the 2017-18 influenza season presented a very high impact in terms of SHCIC rates at all ages, mainly due to hospitalizations in the group over 64 years. In this age group, the highest hospitalization rates were observed this season, since the 2013-14 season. In terms of excess mortality from all causes, the epidemic reached a high impact at all ages group, mainly due to the mortality observed in the group over 64 years. In children under 15 years and young adults, the impact according to excess mortality from all causes was low. In short, the PISA guide allows the estimation of indicators and parameters to assess the severity in seasonal epidemics and possible pandemics. The activity carried out within the framework of the PISA project is a dynamic process in continuous revision, susceptible to improvement as it develops and applies to the different influenza seasons.
- Published
- 2019
38. Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, European Union 2009–2017
- Author
-
Adlhoch, Cornelia, primary, Gomes Dias, Joana, primary, Bonmarin, Isabelle, primary, Hubert, Bruno, primary, Larrauri, Amparo, primary, Oliva Domínguez, Jesús A, primary, Delgado-Sanz, Concepción, primary, Brytting, Mia, primary, Carnahan, Annasara, primary, Popovici, Odette, primary, Lupulescu, Emilia, primary, O’Donnell, Joan, primary, Domegan, Lisa, primary, Van Gageldonk-Lafeber, Arianne B, primary, Meijer, Adam, primary, Kynčl, Jan, primary, Slezák, Pavel, primary, Guiomar, Raquel, primary, Orta Gomes, Carlos M, primary, Popow-Kraupp, Theresia, primary, Mikas, Ján, primary, Staroňová, Edita, primary, Melillo, Jackie M, primary, Melillo, Tanya, primary, Ikonen, Niina, primary, Lyytikäinen, Outi, primary, Snacken, René, primary, and Penttinen, Pasi, primary
- Published
- 2019
- Full Text
- View/download PDF
39. Transmissibility of influenza during the 21st-century epidemics, Spain, influenza seasons 2001/02 to 2017/18.
- Author
-
Redondo-Bravo, Lidia, Delgado-Sanz, Concepción, Oliva, Jesús, Vega, Tomás, Lozano, Jose, and Larrauri, Amparo
- Published
- 2020
- Full Text
- View/download PDF
40. Vigilancia del virus respiratorio sincitial en el marco del Sistema de Vigilancia de la Gripe en España, 2006-2014
- Author
-
Jiménez-Jorge, Silvia, Delgado-Sanz, Concepción, de Mateo, Salvador, Pozo, Francisco, Casas, Inmaculada, and Larrauri, Amparo
- Published
- 2016
- Full Text
- View/download PDF
41. Climatic Factors and Influenza Transmission, Spain, 2010–2015
- Author
-
Gomez-Barroso, Diana, primary, León-Gómez, Inmaculada, additional, Delgado-Sanz, Concepción, additional, and Larrauri, Amparo, additional
- Published
- 2017
- Full Text
- View/download PDF
42. [cycEVA study: case control study measuring influenza vaccine effectiveness in Spain, 2008-2013]
- Author
-
Jiménez-Jorge, Silvia, Mateo Ontañón, Salvador de, Savulescu, Camelia, Delgado-Sanz, Concepción, Pozo Sánchez, Francisco, García-Cenoz, Manuel, Castilla Catalán, Jesús, Rodríguez Gay, Carolina, Vega Alonso, Tomás, Quiñones Rubio, Carmen, Martínez Ochoa, Eva, Vanrell Berga, Juana María, Giménez Durán, Jaume, Castrillejo Pérez, Daniel, Altzíbar Arotzena, Jone Miren, González Carril, Fernando, Ramos Aceitero, Julián Mauro, Serrano Martin, María del Carmen, Martínez i Mateo, Ana, Torner Gràcia, Nuria, Pérez Morilla, Esteban, Gallardo García, Virtudes, Larrauri Cámara, Amparo, European Centre for Disease Prevention and Control (ECDC), Instituto de Salud Carlos III - ISCIII, Centers for Disease Control and Prevention de Estados Unidos, World Health Organization (WHO), and Epiconcept, Francia
- Subjects
Vaccine effectiveness ,Adult ,Male ,Publishing ,Estudios de casos y controles ,Influenza vaccine ,Efectividad vacunal ,Middle Aged ,Gripe humana ,Influenza Vaccines ,Spain ,Case-Control Studies ,Population Surveillance ,Influenza, Human ,Human influenza ,Vigilancia centinela ,Humans ,Female ,Vacuna antigripal ,Seasons ,Sentinel Surveillance - Abstract
Fundamentos: Desde 2008-09 la efectividad de la vacuna (EV) antigripal en España se estima con el estudio de casos y controles para la evaluación de la EV antigripal (cycEVA), componente español de la red europea (Influenza-Monitoring Vaccine Effectiveness (I-MOVE). El objetivo es describir la evolución del estudio cycEVA durante las cinco temporadas del período 2008/09-; 2012/13. Métodos: Se analizaron los siguientes indicadores: 1) participación de los médicos/pediatras centinela (MP); 2) población y periodo de estudio, 3) calidad de los datos y 4) difusión de los resultados mediantes publicaciones. Se calculó el porcentaje anual de cambio constante de los indicadores analizándose su tendencia mediante el test de Cochran-Armitage. Resultados: El número de MP participantes aumentó de 164 en 2008-09 hasta 246 en ediciones posteriores. El porcentaje de médicos que reclutaron al menos un paciente experimentó un cambio anual significativo (PCA) del 15,33%. El porcentaje de pacientes reclutados incluidos en el análisis aumentó del 77% en 2008-09 a más del 95% en las siguientes ediciones (PCA=5,91%). El porcentaje de casos y controles participantes en cycEVA sobre el total de pacientes que contribuyeron al estudio europeo I-MOVE osciló entre el 23% en la edición piloto y 30% en la temporada 2011-12. Los resultados finales se difundieron en revistas científicas con un factor de impacto situado en el cuartil 2 y en 2010-11 y 2011-12 se publicaron resultados preliminares en revistas con un factor de impacto situado en el cuartil 1 (97 citas). Conclusiones: La experiencia del estudio cycEVA se reflejó en una mejora en la oportunidad e impacto de sus resultados, cruciales para orientar las recomendaciones anuales de vacunación antigripal. In Spain, influenza vaccine effectiveness (EV) is estimated since 2008-09 season through the cycEVA case-control study, the Spanish component of the European I-MOVE (Monitoring Influenza Vaccine Effectiveness in the EU/EEA) network. We aimed at describing cycEVA performance in its five consolidated editions 2008/09 -; 2012/13. During the study period the following indicators were analysed: 1) the participation of sentinel general practitioners and pediatricians (MP), 2) the population studied and the study period, 3) the data quality and 4) the dissemination of the cycEVA results. Trend analysis of the indicators was done using the Cochran-Armitage test to compute the Annual Percentage Change (PCA). The number of participating MP increased from 164 in 2008-09 to 246 in the following editions. The percentage of MP recruiting at least one patient increased significantly annually (PCA = 15.33%). The percentage of recruited patients included into the analysis increased (PCA=5.91%) from 77% in 2008-09 to more than 95% in the following editions. The percentage of cycEVA patients contributing to the I-MOVE study ranged between 23% and 30% in the pilot and 2011-12 editions respectively.. Final results were disseminated in quartile 2 peer-reviewed journals and 2010-11 and 2011-12 preliminary EV estimates were published in quartile 1 journals. cycEVA publications received 97 citations. cycEVA study achieved more quality information, timely EV estimates and a higher impact of the results. El estudio fue financiado por el European Centre for Disease Prevention and Control (ECDC tender OJ/2007/07/30-PROC/2007/015) a través de la Red para la vigilancia de la efectividad de la vacuna antigripal en Europa (I-MOVE) y por el Instituto de Salud Carlos III [Programa de Investigación sobre la nueva Gripe AH1N1Influenza A(H1N1)pdm09 Programme (GR09/0017)]. Este proyecto recibió financiación adicional del Centers for Disease Control and Prevention de Estados Unidos, de la Oficina Europea de la Organización Mundial de la Salud y de Epiconcept, Francia. No existen conflictos de intereses. Sí
- Published
- 2014
43. Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16.
- Author
-
Mazagatos, Clara, Delgado-Sanz, Concepción, Oliva, Jesús, Gherasim, Alin, Larrauri, Amparo, and null, null
- Subjects
- *
MATERNAL health , *INFLUENZA vaccines , *INFLUENZA prevention , *WOMEN'S health , *PUBLIC health - Abstract
Based on previous observations during pandemics and seasonal epidemics, pregnant women are considered at risk of developing severe influenza outcomes after influenza infection. With the aim of preventing severe influenza illness, the World Health Organization (WHO) includes pregnant women as a target group for seasonal influenza vaccination. However, influenza vaccine uptake during pregnancy remains low in many countries, including Spain. The objectives of this study were to increase the evidence of pregnancy as a risk factor for severe influenza illness and to study the potential role of seasonal influenza vaccination in the prevention of severe outcomes in infected pregnant women. Using information from the surveillance of Severe Hospitalized Confirmed Influenza Cases (SHCIC) in Spain, from seasons 2010/11 to 2015/16, we estimated that pregnant women in our study had a relative risk of hospitalization with severe influenza nearly 7.8 times higher than non-pregnant women of reproductive age. Only 5 out of 167 pregnant women with known vaccination status in our study had been vaccinated (3.6%). Such extremely low vaccination coverage only allowed obtaining crude estimates suggesting a protective effect of the vaccine against influenza complications (ICU admission or death). Our overall results support that pregnant women could benefit from seasonal influenza vaccination, in line with national and international recommendations. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
44. Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010‐2016.
- Author
-
Oliva, Jesús, Delgado‐Sanz, Concepción, Larrauri, Amparo, and the Spanish Influenza Surveillance System
- Subjects
- *
SEASONAL influenza , *PUBLIC health surveillance , *PRIMARY care , *BURDEN of care , *HOSPITALS - Abstract
Background: Estimating the national burden of influenza disease is challenging. We aimed to estimate the disease burden of seasonal influenza in Spain, at the primary care and hospital level, over the 6 influenza seasons after 2009 pandemic. Methods: We used data from the Spanish Influenza Sentinel Surveillance System to estimate weekly influenza rates and the number of influenza‐like illness (ILI) and mild confirmed influenza cases (MCIC). From the surveillance of severe hospitalized confirmed influenza cases (SHCIC), we obtained hospitalization rates and total number of SHCIC, intensive care unit (ICU) admissions and deaths in influenza hospitalized patients. We estimated both mild and severe influenza cases, overall, and by age‐group (<5, 5‐14, 15‐64, and ≥65 years). Results: The highest cumulative rates of MCIC were observed in <15 years (1395‐3155 cases/100 000 population in 5‐14 years) and the lowest in ≥65 years (141‐608 cases/100 000 population). SHCIC rates revealed a characteristic U‐shaped distribution, with annual average hospitalization rates of 16.5 and 18.9 SHCIC/100, 000 p in 0‐4 years, and ≥65 years, respectively. We estimated an annual average of 866 868 cases of ILI attended in primary care (55% were MCIC), 3616 SHCIC, 1232 ICU admissions, and 437 deaths in SHCIC. The percentage of ICU admission among SHCIC was highest at 15‐64 years (42%), while the hospitalization fatality rate ranged from 1% in 0‐4 years to 18% in ≥65 years. Conclusions: The ongoing Spanish Influenza Surveillance System allowed obtaining crucial information regarding the impact of mild and severe influenza in Spain. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
45. Estudio cycEVA: casos y controles para la estimación de la efectividad de la vacuna antigripal en España, 2008-2013
- Author
-
Jiménez-Jorge, Silvia, primary, Mateo Ontañón, Salvador de, additional, Savulescu, Camelia, additional, Delgado-Sanz, Concepción, additional, Pozo Sánchez, Francisco, additional, García-Cenoz, Manuel, additional, Castilla Catalán, Jesús, additional, Rodríguez Gay, Carolina, additional, Vega Alonso, Tomás, additional, Quiñones Rubio, Carmen, additional, Martínez Ochoa, Eva, additional, Vanrell Berga, Juana María, additional, Giménez Durán, Jaume, additional, Castrillejo Pérez, Daniel, additional, Altzíbar Arotzena, Jone Miren, additional, González Carril, Fernando, additional, Ramos Aceitero, Julián Mauro, additional, Serrano Martin, María del Carmen, additional, Martínez i Mateo, Ana, additional, Torner Gràcia, Nuria, additional, Pérez Morilla, Esteban, additional, Gallardo García, Virtudes, additional, and Larrauri Cámara, Amparo, additional
- Published
- 2014
- Full Text
- View/download PDF
46. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
- Author
-
Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Baruch J, Denayer S, Seyler L, Domegan L, Launay O, Machado A, Burgui C, Vaikutyte R, Niessen FA, Loghin II, Husa P, Aouali N, Panagiotakopoulos G, Tolksdorf K, Horváth JK, Howard J, Pozo F, Gallardo V, Nonković D, Džiugytė A, Bossuyt N, Demuyser T, Duffy R, Luong Nguyen LB, Kislaya I, Martínez-Baz I, Gefenaite G, Knol MJ, Popescu C, Součková L, Simon M, Michelaki S, Reiche J, Ferenczi A, Delgado-Sanz C, Lovrić Makarić Z, Cauchi JP, Barbezange C, Van Nedervelde E, O'Donnell J, Durier C, Guiomar R, Castilla J, Jonikaite I, Bruijning-Verhagen PC, Lazar M, Demlová R, Wirtz G, Amerali M, Dürrwald R, Kunstár MP, Kissling E, Bacci S, and Valenciano M
- Subjects
- Humans, Adult, COVID-19 Vaccines, Vaccine Efficacy, SARS-CoV-2, Hospitalization, Europe epidemiology, RNA, Messenger, COVID-19 prevention & control, Pneumonia
- Abstract
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period).MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition.ResultsWe included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively.ConclusionsOur results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.
- Published
- 2023
- Full Text
- View/download PDF
47. Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020.
- Author
-
Vestergaard LS, Nielsen J, Richter L, Schmid D, Bustos N, Braeye T, Denissov G, Veideman T, Luomala O, Möttönen T, Fouillet A, Caserio-Schönemann C, An der Heiden M, Uphoff H, Lytras T, Gkolfinopoulou K, Paldy A, Domegan L, O'Donnell J, De' Donato F, Noccioli F, Hoffmann P, Velez T, England K, van Asten L, White RA, Tønnessen R, da Silva SP, Rodrigues AP, Larrauri A, Delgado-Sanz C, Farah A, Galanis I, Junker C, Perisa D, Sinnathamby M, Andrews N, O'Doherty M, Marquess DF, Kennedy S, Olsen SJ, Pebody R, Krause TG, and Mølbak K
- Subjects
- Adolescent, Adult, Age Distribution, Aged, Aged, 80 and over, Betacoronavirus, COVID-19, Child, Child, Preschool, Coronavirus Infections diagnosis, Disease Outbreaks, Europe epidemiology, Female, Humans, Infant, Infant, Newborn, Influenza, Human diagnosis, Male, Middle Aged, Mortality trends, Pandemics, Pneumonia, Viral diagnosis, Population Surveillance, Preliminary Data, SARS-CoV-2, Young Adult, Cause of Death trends, Coronavirus isolation & purification, Coronavirus Infections mortality, Influenza, Human mortality, Pneumonia, Viral mortality
- Abstract
A remarkable excess mortality has coincided with the COVID-19 pandemic in Europe. We present preliminary pooled estimates of all-cause mortality for 24 European countries/federal states participating in the European monitoring of excess mortality for public health action (EuroMOMO) network, for the period March-April 2020. Excess mortality particularly affected ≥ 65 year olds (91% of all excess deaths), but also 45-64 (8%) and 15-44 year olds (1%). No excess mortality was observed in 0-14 year olds.
- Published
- 2020
- Full Text
- View/download PDF
48. Transmissibility of influenza during the 21st-century epidemics, Spain, influenza seasons 2001/02 to 2017/18.
- Author
-
Redondo-Bravo L, Delgado-Sanz C, Oliva J, Vega T, Lozano J, and Larrauri A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Epidemiological Monitoring, Female, Humans, Infant, Infant, Newborn, Influenza A Virus, H1N1 Subtype isolation & purification, Influenza, Human epidemiology, Influenza, Human virology, Male, Middle Aged, Seasons, Spain epidemiology, Time Factors, Young Adult, Disease Notification methods, Epidemics, Influenza, Human transmission, Sentinel Surveillance
- Abstract
BackgroundUnderstanding influenza seasonality is necessary for determining policies for influenza control.AimWe characterised transmissibility during seasonal influenza epidemics, including one influenza pandemic, in Spain during the 21th century by using the moving epidemic method (MEM) to calculate intensity levels and estimate differences across seasons and age groups.MethodsWe applied the MEM to Spanish Influenza Sentinel Surveillance System data from influenza seasons 2001/02 to 2017/18. A modified version of Goldstein's proxy was used as an epidemiological-virological parameter. We calculated the average starting week and peak, the length of the epidemic period and the length from the starting week to the peak of the epidemic, by age group and according to seasonal virus circulation.ResultsIndividuals under 15 years of age presented higher transmissibility, especially in the 2009 influenza A(H1N1) pandemic. Seasons with dominance/co-dominance of influenza A(H3N2) virus presented high intensities in older adults. The 2004/05 influenza season showed the highest influenza-intensity level for all age groups. In 12 seasons, the epidemic started between week 50 and week 3. Epidemics started earlier in individuals under 15 years of age (-1.8 weeks; 95% confidence interval (CI):-2.8 to -0.7) than in those over 64 years when influenza B virus circulated as dominant/co-dominant. The average time from start to peak was 4.3 weeks (95% CI: 3.6-5.0) and the average epidemic length was 8.7 weeks (95% CI: 7.9-9.6).ConclusionsThese findings provide evidence for intensity differences across seasons and age groups, and can be used guide public health actions to diminish influenza-related morbidity and mortality.
- Published
- 2020
- Full Text
- View/download PDF
49. [Monitoring respiratory syncytial virus through the Spanish influenza surveillance system, 2006-2014].
- Author
-
Jiménez-Jorge S, Delgado-Sanz C, de Mateo S, Pozo F, Casas I, and Larrauri A
- Subjects
- Humans, Influenza, Human epidemiology, Population Surveillance, Respiratory Syncytial Virus, Human, Spain epidemiology, Respiratory Syncytial Virus Infections epidemiology
- Abstract
Introduction: The aim of the study is to analyze the information on respiratory syncytial virus (RSV) obtained through the Spanish Influenza Surveillance System (SISS) and to study its usefulness as supplementary information for the characterization of influenza epidemics., Methods: The temporal patterns of both RSV and influenza viruses were analyzed by patterns comparing the weekly viral detection rates from 2006 to 2014., Results: In general, the RSV circulation was characterized by showing a peak between 52-1 weeks, and circulated from 2 to 8 weeks before/prior to influenza viruses., Conclusion: RSV information obtained from the SISS is useful for the characterization of influenza epidemics in Spain., (Copyright © 2015 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.